2024
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Lee B, Witkiewitz K, Mellinger J, Anania F, Bataller R, Cotter T, Curtis B, Dasarathy S, DeMartini K, Diamond I, Diazgranados N, DiMartini A, Falk D, Fernandez A, German M, Kamath P, Kidwell K, Leggio L, Litten R, Louvet A, Lucey M, McCaul M, Sanyal A, Singal A, Sussman N, Terrault N, Thursz M, Verna E, Radaeva S, Nagy L, Mitchell M. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nature Reviews Gastroenterology & Hepatology 2024, 21: 626-645. PMID: 38849555, DOI: 10.1038/s41575-024-00936-x.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAlcohol use disorderLiver diseaseClinical trialsRisk of decompensation of liver diseaseAlcohol useUse disorderTreatment of alcohol use disordersExpert panel consensus statementDecompensation of liver diseaseAddiction medicine specialistsProgression of liver diseaseLiver-related outcomesNational Institute of Alcohol AbuseDesigning clinical trialsEffects of alcohol useConsensus of expert opinionTask ForceConsensus statementMedicine specialistsAlcohol abuseHeavy drinkingDiseaseClinical trialistsPatients
2022
Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation
Waddell JT, Corbin WR, MacKinnon DP, Leeman RF, DeMartini KS, Fucito LM, Kranzler HR, O’Malley S. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. Alcohol Clinical And Experimental Research 2022, 46: 477-491. PMID: 35076087, PMCID: PMC9679805, DOI: 10.1111/acer.14780.Peer-Reviewed Original ResearchConceptsMedication dosageYoung adultsLight drinkingSubjective responsesSubjective effectsHeavy drinkingPlacebo-controlled studyEffect sizePerson effectsEffective treatmentNaltrexoneDrinking daysNaltrexone efficacySmall effect sizesDrinking levelsCravingDrinkingAdultsLaboratory-based studiesPillsMomentary assessmentEfficacyTreatment conditionsDrinking environmentsDaily diary data
2020
Drinking and responses to antidrinking messages among young adults: An fMRI study
Garrison KA, DeMartini KS, Corlett PR, Worhunsky PD, Krystal JH, O'Malley SS. Drinking and responses to antidrinking messages among young adults: An fMRI study. Addiction Biology 2020, 26: e12882. PMID: 32068323, PMCID: PMC7431375, DOI: 10.1111/adb.12882.Peer-Reviewed Original ResearchConceptsDrinking cuesNeural responsesYoung adultsFunctional magnetic resonanceSelf-reported drinkingPast monthNeutral cuesDrug cuesSmoking cuesHabitual responsesReward processingFMRI studyDrinking quantityCuesDependent individualsSubstance useAlcohol useBinge drinkingNegative consequencesGreater baselinePublic health campaignsExcessive drinkingHeavy drinkingHealth campaignsDrinking
2016
Urgency traits moderate daily relations between affect and drinking to intoxication among young adults
Bold KW, Fucito LM, DeMartini KS, Leeman RF, Kranzler HR, Corbin WR, O’Malley S. Urgency traits moderate daily relations between affect and drinking to intoxication among young adults. Drug And Alcohol Dependence 2016, 170: 59-65. PMID: 27875802, PMCID: PMC5183550, DOI: 10.1016/j.drugalcdep.2016.10.035.Peer-Reviewed Original ResearchConceptsYoung adultsHeavy drinkingEffectiveness of naltrexoneBlood alcohol concentrationHeavy drinking young adultsBrief motivational interventionNaltrexone treatmentClinical trialsHazardous drinkingNaltrexoneSecondary analysisPlaceboTargeted interventionsAge 18Alcohol useIntoxicationLow urgencyAdultsMotivational interventionDrinkingTrait urgencyOddsInterventionCurrent studyRiskRandomized Controlled Trial of a Very Brief, Multicomponent Web-Based Alcohol Intervention for Undergraduates With a Focus on Protective Behavioral Strategies
Leeman RF, DeMartini KS, Gueorguieva R, Nogueira C, Corbin WR, Neighbors C, O’Malley S. Randomized Controlled Trial of a Very Brief, Multicomponent Web-Based Alcohol Intervention for Undergraduates With a Focus on Protective Behavioral Strategies. Journal Of Consulting And Clinical Psychology 2016, 84: 1008-1015. PMID: 27599223, PMCID: PMC5332163, DOI: 10.1037/ccp0000132.Peer-Reviewed Original ResearchConceptsHeavy drinkingWeb-based alcohol interventionPast-month heavy drinkingPeak drinkingControl conditionAlcohol-related problemsBrief interventionAlcohol interventionsYoung adultsInterventionWeeksSignificant differencesDrinkingMonthsDrinksFocused listPBSAssessment controlResearch interventionsFirst studyCondition participantsDaily Relations Among Affect, Urge, Targeted Naltrexone, and Alcohol Use in Young Adults
Bold KW, Fucito LM, Corbin WR, DeMartini KS, Leeman RF, Kranzler HR, O’Malley S. Daily Relations Among Affect, Urge, Targeted Naltrexone, and Alcohol Use in Young Adults. Experimental And Clinical Psychopharmacology 2016, 24: 367-375. PMID: 27690505, PMCID: PMC5111359, DOI: 10.1037/pha0000090.Peer-Reviewed Original ResearchConceptsYoung adultsDouble-blind clinical trialHeavy drinkingSerious public health problemDose of medicationPublic health problemAlcohol-related interventionsTargeted naltrexoneNaltrexone groupOpioid antagonistRisk factorsClinical trialsFamily historyNaltrexone effectsGreater oddsAlcohol consumptionHealth problemsAlcohol dependenceSecondary analysisPlaceboNaltrexoneNaltrexone's abilityAdultsMedicationsDrinkingLongitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers
DeMartini KS, Gueorguieva R, Leeman RF, Corbin WR, Fucito LM, Kranzler HR, O’Malley S. Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers. Journal Of Consulting And Clinical Psychology 2016, 84: 185-190. PMID: 26654213, PMCID: PMC4941818, DOI: 10.1037/ccp0000053.Peer-Reviewed Original ResearchConceptsPercent days abstinentFirst placebo-controlled trialPercent days heavy drinkingHeavy drinkingPlacebo-controlled trialLong-term outcomesHeavy drinking daysYoung adults ages 18Adults ages 18Naltrexone conditionActive medicationPlacebo groupPharmacotherapy trialsAdult heavy drinkersYoung adult heavy drinkersNonsignificant decreaseSignificant benefitsYear posttreatmentDays abstinentDrinking daysMost outcomesSingle interventionHeavy drinkersTreatment improvementAge 18